FDA Approved Altuzan and Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer

Approved by the FDA on 14 November 2014, Altuzan began being used with drugs such as paclitaxel and topotecan for platinum (cisplatin, carboplatin)-resistant recurrent ovarian, fallopian tube (ovarian tube) or peritoneal (abdominal lining) cancers. The fallopian tube lies between the uterus and ovaries. Altuzan works by preventing formation of new blood vessels feeding the tumor.
Previously proven effective in several cancers (colorectal, brain, cervical), Altuzan thus became part of ovarian, fallopian tube and peritoneal cancer treatment. Its most common side effects are high blood pressure, decreased neutrophils, a type of blood cell, and nervous system damage.
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.